EARLY DETECTION OF COLORECTAL CANCER Colorectal cancer (CRC) is a common disease affecting over a million people annually worldwide. Most colorectal cancer screening recommendations call for screening beginning at age 50. The most common screening test, the Fecal Occult Blood Test (FOBT), is noted for poor sensitivity of 30% and high specificity. Recommendations in some countries also include periodic endoscopic procedures, or colonoscopy. While these procedures are sensitive and specific for identifying precancerous or cancerous lesions, they are invasive and costly. As a result less than 50% of the targeted U.S. and European population have complied with screening recommendations. BioMarCare Technologies is developing a multivariate tool of tumor specific markers that provides superior sensitivity and specificity as compared to the FOBT test. METASTATIC COLORECTAL CANCER (mCRC) There are about 1,200,000 new cases of CRC around the world with over 500K newly diagnosed patients a year in the western world. 40-50% of all newly diagnosed colorectal cancer will develop metastases. Despite early diagnosis and treatment, cancers involving the colon or rectum can reappear at a later time, even if the cancer was entirely removed during the initial treatment. A colorectal cancer recurrence can be either local (confined to the large intestine or nearby tissues) or at a distant site like the liver. In other cases, a colorectal cancer will have already spread to distant sites by the time it is diagnosed. This is also referred to as metastatic colorectal cancer (stage IV). Complete cure is not possible for most patients with metastatic colorectal cancer (mCRC), although some patients who have limited involvement (particularly restricted to the liver or lung) can be cured with surgery. For others, chemotherapy is the most appropriate option. Chemotherapy does not cure mCRC, but it can improve symptoms and prolong life. Chemotherapy has been the mainstay of treatment for mCRC for many years and was incorporated into first- and second-line treatment strategies. The development of biological therapies that are tumor specific with better toxicity profiles has widened the spectrum of therapies for this disease. New biological therapies are improving clinical outcome for patients with mCRC.